Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum …
S Patel, JD Patel - Advances in Therapy, 2023 - Springer
Patients with metastatic epidermal growth factor receptor (EGFR)-mutated non-small cell
lung cancer (NSCLC) are widely treated with osimertinib, the preferred first-line treatment …
lung cancer (NSCLC) are widely treated with osimertinib, the preferred first-line treatment …
[HTML][HTML] Nonproportional hazards in network meta-analysis: efficient strategies for model building and analysis
Objectives To develop efficient approaches for fitting network meta-analysis (NMA) models
with time-varying hazard ratios (such as fractional polynomials and piecewise constant …
with time-varying hazard ratios (such as fractional polynomials and piecewise constant …
[HTML][HTML] A Comparison of alternative network meta-analysis methods in the presence of nonproportional hazards: a case study in first-line advanced or metastatic …
Objectives Network meta-analysis (NMA) of time-to-event outcomes based on constant
hazard ratios can result in biased findings when the proportional hazards (PHs) assumption …
hazard ratios can result in biased findings when the proportional hazards (PHs) assumption …
Network pharmacology study of Citrus reticulata and Pinellia ternata in the treatment of non-small cell lung cancer
C Li, H Lu, X Jiang, X Guo, H Zhong… - Cellular and Molecular …, 2021 - cellmolbiol.org
It has been recognized that Citrus reticulata and Pinellia ternata have a good therapeutic
effect on NSCLC. However, the potential mechanism of C. reticulata and P. ternata in the …
effect on NSCLC. However, the potential mechanism of C. reticulata and P. ternata in the …
The top 100 most frequently cited publications concerning anti-PD-1/PD-L1 therapy for lung cancer: A bibliometric analysis
Y Li, M Lv, J Liu, J Ma, M Liang… - Cancer management and …, 2021 - Taylor & Francis
Background Globally lung cancer is one of the most common cancers, and is responsible for
almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD …
almost 20% of all cancer care costs. As a potential treatment for lung cancer, anti-PD-1/PD …
Benchmarking single-arm studies against historical controls from non-small cell lung cancer trials–an empirical analysis of bias
K Snyders, D Cho, JH Hong, S Lord, R Asher… - Acta …, 2020 - Taylor & Francis
Background: Recent trials of novel agents in 'rare'molecular subtypes of non-small cell lung
cancer (NSCLC) have used single-arm trial designs and benchmarked outcomes against …
cancer (NSCLC) have used single-arm trial designs and benchmarked outcomes against …
Clinical Trial and Real-World Outcomes of Patients With Metastatic NSCLC in the Post-Platinum–Based Chemotherapy Failure Setting
YY Soon, W Furnback, J Kim, PY Chuang… - JTO Clinical and …, 2023 - Elsevier
Introduction A literature review was undertaken to identify clinical trials and real-world
studies of patients with stage IV NSCLC who had progressed on or after treatment with …
studies of patients with stage IV NSCLC who had progressed on or after treatment with …
Bayesian multivariate network meta‐analysis model for the difference in restricted mean survival times
X Tang, L Trinquart - Statistics in medicine, 2022 - Wiley Online Library
Network meta‐analysis (NMA) is essential for clinical decision‐making. NMA enables
inference for all pair‐wise comparisons between interventions available for the same …
inference for all pair‐wise comparisons between interventions available for the same …
[PDF][PDF] Successful treatment of therapy-related acute promyelocytic leukemia with all-trans-retinoic acid following epirubicin for hepatocellular carcinoma and docetaxel …
R Suzuki, H Kawai, D Furuya, H Akashi, Y Ogawa… - Tokai J Exp Clin …, 2020 - tma1975.org
A 69-year-old man was referred to the hematology department for the evaluation of
pancytopenia. He had been treated with radiation and epirubicin for hepatocellular …
pancytopenia. He had been treated with radiation and epirubicin for hepatocellular …
[PDF][PDF] PD-1, PD-L1 的表达与肺癌临床病理特征及预后的相关性分析
孔明， 陈雯， 刘坤坤， 王哲… - Progress in Modern …, 2020 - biomed.cnjournals.com
摘要目的: 分析程序性死亡因子-1 (PD-1), 程序性死亡1-配体(PD-L1) 的表达与肺癌临床病理
特征及预后的相关性. 方法: 回顾性分析我院2015 年3 月~ 2016 年6 月收治的73 …
特征及预后的相关性. 方法: 回顾性分析我院2015 年3 月~ 2016 年6 月收治的73 …